Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way—building ...

de la Fuente-Nunez is a presidential associate professor at the University of Pennsylvania. Skinner is CEO of the AMR Action Fund. Of all the areas of drug development that artificial intelligence has ...

Antibiotic resistance is making bacterial infections harder to treat, demanding new therapeutic strategies. A new review ...

Drug companies are more likely to keep research and development (R&D) in-house, rather than outsource it, when they already ...

Antibiotics are a crucial tool in the fight against bacterial infections. But the World Health Organization has long warned that we are facing an antibiotic crisis. Bacteria can easily adapt, evolve, ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Accelerated drug development expertise. For small startups and academic spinoffs bringing their first molecules to market, ...

This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science.

The world urgently needs new antibiotics, yet the market routinely punishes companies that take on the long, risky and ...

Although the past decade has been marked by lack of innovation in the field of antibiotics development, that trend is changing, according to data from Reportlinker. According to the data, 109 ...